Relmada Therapeutics (NASDAQ:RLMD) versus Alseres Pharmaceuticals (OTCMKTS:ALSE) Critical Review

Relmada Therapeutics (NASDAQ:RLMD) and Alseres Pharmaceuticals (OTCMKTS:ALSE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Relmada Therapeutics and Alseres Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1	1	4	1	2.71
Alseres Pharmaceuticals	0	0	0	0	0.00

Relmada Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 86.63%. Given Relmada Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Relmada Therapeutics is more favorable than Alseres Pharmaceuticals.

Valuation & Earnings

This table compares Relmada Therapeutics and Alseres Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38 million	($1.45)	-4.43
Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Insider & Institutional Ownership

45.2% of Relmada Therapeutics shares are held by institutional investors. 20.7% of Relmada Therapeutics shares are held by company insiders. Comparatively, 8.9% of Alseres Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Relmada Therapeutics and Alseres Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-170.83%	-145.58%
Alseres Pharmaceuticals	N/A	N/A	N/A

Summary

Relmada Therapeutics beats Alseres Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

About Relmada Therapeutics

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

About Alseres Pharmaceuticals

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson’s disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.